TBD.F · Emerald Health Therapeutics, Inc

-

Please sign in to comment on TBD.F

1 Comment

Admin

4 years ago

Emerald Health Therapeutics, Inc is currently in a long term downtrend where the price is trading 19.8% below its 200 day moving average.

From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.1.

Emerald Health Therapeutics, Inc's total revenue sank by 63.7% to $3M since the same quarter in the previous year.

Its net income has increased by 33.4% to $-11M since the same quarter in the previous year.

Finally, its free cash flow grew by 96.2% to $-541K since the same quarter in the previous year.

Based on the above factors, Emerald Health Therapeutics, Inc gets an overall score of 3/5.

CurrencyCode	EUR
Exchange	F
Sector
Industry
ISIN	None

Market Cap	5M
PE Ratio	None
Target Price	None
Dividend Yield	0.0%
Beta	0.63

ABOUT

Emerald Health Therapeutics, Inc

Emerald Health Therapeutics, Inc., together with its subsidiaries, engages in the production, distribution, and sale of recreational and medical cannabis in Canada. It offers dried cannabis strains, pre-rolled cannabis, oral sprays, nano emulsion shots, and cannabis oil products under the SYNC Wellness, fuse, Emerald, and Souvenir brands. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada. As of November 10, 2022, Emerald Health Therapeutics, Inc. operates as a subsidiary of Skye Bioscience, Inc.

TBD.F · Emerald Health Therapeutics, Inc

-

Emerald Health Therapeutics, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Emerald Health Therapeutics, Inc using a moving average strategy